Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pivalate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pivalate SCHEMBL3197117 | 0.93 | FFAR3 (0.50) | FFAR3LCKFYNTSHRALDH1A1 | |
| Pivalate SCHEMBL27877695 | 0.92 | TSHR (0.53) | FFAR3LCKFYNTSHRALDH1A1 | |
| Pivalate SCHEMBL3613 | 0.91 | — | — | |
| Pivalate SCHEMBL4318862 | 0.91 | — | — | |
| Pivalate SCHEMBL5116637 | 0.91 | TSHR (0.61) | FFAR3LCKFYNTSHRALDH1A1 | |
| Pivalate SCHEMBL332912 | 0.91 | TSHR (0.61) | FFAR3LCKFYNTSHRALDH1A1 | |
| Pivalate SCHEMBL23001579 | 0.87 | — | — | |
| Pivalate SCHEMBL1685641 | 0.87 | — | — | |
| Pivalate SCHEMBL6516524 | 0.87 | — | — | |
| Pivalate SCHEMBL15771206 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076477-A1 | POLY ALPHA-1,3-GLUCAN ESTERS AND ARTICLES MADE THEREFROM | NUTRITION & BIOSCIENCES USA 4 INC (US) | 2024-03-07 | — | — | US | disclosed |
| EP-3559056-B1 | USE OF AT LEAST ONE PHENOLIC COMPOUND TO STABILISE ETHYLENE COPOLYMERISATION REACTIONS | SK GEO CENTRIC CO LTD (KR) | 2024-02-14 | — | — | EP | disclosed |
| US-20230192905-A1 | POLYALPHA-1,3-GLUCAN ESTERS AND ARTICLES MADE THEREFROM | Nutrition & Biosciences USA 4, Inc. | 2023-06-22 | — | — | US | disclosed |
| CN-111936579-B | Use of ethylene and acrylate copolymers prepared in a tubular reactor for modifying the melt rheology of thermoplastic compositions | 爱思开致新株式会社 | 2023-05-09 | — | — | CN | disclosed |
| US-11555116-B2 | Use of a copolymer of ethylene and of acrylate(s) prepared in a tubular reactor for modifying the melt rheology of a thermoplastic composition | SK GLOBAL CHEMICAL CO., LTD. (KR) | 2023-01-17 | — | — | US | disclosed |
| EP-3902844-A2 | USE OF AT LEAST ONE HEMO-PEROXYACETAL, ALONE OR IN COMBINATION WITH OTHER PEROXIDES, TO PROMOTE POLYMERISATION OR COPOLYMERISATION OF ETHYLENE UNDER HIGH PRESSURE | ARKEMA FRANCE (FR) | 2021-11-03 | — | — | EP | disclosed |
| US-20210163739-A1 | Use of a Copolymer of Ethylene and of Acrylate(s) Prepared in a Tubular Reactor for Modifying the Melt Rheology of a Thermoplastic Composition | SK GEO CENTRIC CO., LTD. (KR) | 2021-06-03 | — | — | US | disclosed |
| CN-112638952-A | Use of at least one hemiperoxy acetal, alone or in combination with other peroxides, for promoting the polymerization or copolymerization of ethylene at high pressure | 阿科玛法国公司 | 2021-04-09 | — | — | CN | disclosed |
| EP-3775045-A1 | USE OF A COPOLYMER OF ETHYLENE AND OF ACRYLATE(S) PREPARED IN A TUBULAR REACTOR FOR MODIFYING THE MELT RHEOLOGY OF A THERMOPLASTIC COMPOSITION | SK Global Chemical Co., Ltd. (KR) | 2021-02-17 | — | — | EP | disclosed |
| CN-111936579-A | Use of ethylene and acrylate copolymers prepared in a tubular reactor for modifying the melt rheology of thermoplastic compositions | SK综合化学株式会社 | 2020-11-13 | — | — | CN | disclosed |
| JP-2006111797-A | OPTICAL FILM, POLARIZING PLATE, AND LIQUID CRYSTAL DISPLAY DEVICE | KONICA MINOLTA OPTO INC | 2006-04-27 | — | — | JP | disclosed |
| US-20050192299-A1 | Method of treating or preventing hepatitis B virus | CHENG YUNG-CHI (US) | 2005-09-01 | — | — | US | disclosed |
| US-6632958-B1 | An alkene (1) is added to cyclopentenone (2) under the action of an alkyl lithium and an organic copper reagent to form an adduct, said adduct is reacted with e.g. a carboxylic anhydride (4) to obtain a prostaglandin derivative, which is | MITSUBISHI PHARMA CORPORATION (JP) | 2003-10-14 | — | — | US | disclosed |
| EP-1085012-A1 | PROCESS FOR PRODUCING PURIFIED PROSTAGLANDIN DERIVATIVE | Asahi Glass Co., Ltd. (JP) | 2001-03-21 | — | — | EP | disclosed |
| US-5559249-A | 7'-amino-naphthazarin antibiotic derivatives | GRUPPO LEPETIT SPA (IT) | 1996-09-24 | — | — | US | disclosed |
| US-5530133-A | VAGINAL INFECTIONS | GRUPPO LEPETIT SPA (IT) | 1996-06-25 | — | — | US | disclosed |
| US-5475010-A | Vaginal infections | GRUPPO LEPETIT S.P.A. (IT) | 1995-12-12 | — | — | US | disclosed |
| EP-0641346-A1 | 7'-AMINO-NAPHTHAZARIN ANTIBIOTIC DERIVATIVES. | LEPETIT SPA (IT) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993012115-A1 | 7'-AMINO-NAPHTHAZARIN ANTIBIOTIC DERIVATIVES | GRUPPO LEPETIT S.P.A. (IT) | 1993-06-24 | — | — | WO | disclosed |
| WO-1992018517-A1 | METHOD OF TREATING OR PREVENTING HEPATITIS B VIRUS | YALE UNIVERSITY (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192299-A1 | Method of treating or preventing hepatitis B virus | CDA, DCTD, TTPA | FFAR3 2955/4885LCK 2951/4885FYN 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.